UNSPSC 51332867: Perphenazine sulfoxide

This classification denotes an antipsychotic agent with the molecular formula C21H26ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6Q9MQ62M, chemically known as perphenazine sulfoxide, (+/-)-, but more generally known as perphenazine sulfoxide, which bears US NIH Compound Identifier 82341. European Medicines Agency schedules perphenazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG.

Most nations, for tariff purposes, schedule perphenazine sulfoxide under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3[S+]2[O-])CL)CCCN4CCN(CC4)CCO.

UNSPSC 51332867 Perphenazine sulfoxide is a Commodity code that nominally designates a specific pharmaceutical compound, but recent state and local solicitations tagged with this code show minimal direct procurement activity for the named chemical and instead reflect broader pharmaceutical supply and pharmacy benefit management initiatives. State and local governments are using this code to solicit naloxone and drug deactivation systems (county-level public health procurement), generic multi-source pharmaceuticals and OTC products through cooperative purchasing alliances, and exploratory vendor capability information for direct-to-manufacturer pharmacy benefit programs. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing organizations, indicating that pharmaceutical procurement at the state and local level typically flows through aggregated purchasing vehicles or cooperative alliances rather than individual jurisdiction buys.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing a multi-jurisdictional procurement mechanism that includes Oregon and other participating states. Representative recent opportunities include Seminole County, Florida's IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's Request for Information (HHS0017013, posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers with pricing effective July 1, 2026. The code shows limited relevance to perphenazine sulfoxide specifically; state and local procurement under this UNSPSC designation appears to address pharmaceutical supply chains and pharmacy benefit administration more broadly, suggesting potential tagging misalignment or category consolidation in the posting systems.